Home
Home

obesity

Vivus Rises On Wider Coverage Of Qsymia

Vivus Rises On Wider Coverage Of Qsymia
Seeking Alpha

Orexigen: Is Contrave The Long-Term Winner In The Anti-Obesity Drug Wars?

Orexigen: Is Contrave The Long-Term Winner In The Anti-Obesity Drug Wars?
Seeking Alpha

Vivus shares jump on strong growth in Qsymia prescriptions

Vivus shares jump on strong growth in Qsymia prescriptions
Reuters

Investor Enthusiasm Wanes For Obesity Drug Companies

Investor Enthusiasm Wanes For Obesity Drug Companies
Seeking Alpha

The Looming EU Approval Makes Arena Pharmaceuticals Significantly Undervalued

The Looming EU Approval Makes Arena Pharmaceuticals Significantly Undervalued
Motley Fool

10 Drugs Approved by the FDA in 2012 to Be Thankful For

10 Drugs Approved by the FDA in 2012 to Be Thankful For
Motley Fool

Assessing Arena's Belviq As A Diabesity Drug

Assessing Arena's Belviq As A Diabesity Drug
Seeking Alpha

Analyst Debate: Is Arena Pharmaceuticals a Top Stock?

Analyst Debate: Is Arena Pharmaceuticals a Top Stock?
Motley Fool

3 Biopharmaceuticals Weighed By Uncertainty

3 Biopharmaceuticals Weighed By Uncertainty
Seeking Alpha

Glaxo Doubts GLP-1s Would Be Cleared as Drugs for Obesity

Glaxo Doubts GLP-1s Would Be Cleared as Drugs for Obesity
Bloomberg